RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q3 FY21 results · Oct–Dec 2020
RPG Life Sciences reported revenue from operations of ₹107.60 crore (up 14.0% from Q3 FY20) and net profit of ₹12.87 crore (up 62.7% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 107.60 | 94.37 | +14.0% | 97.13 | +10.8% |
| Other income | 0.12 | 0.04 | +200.0% | 0.04 | +200.0% |
| Total income | 107.72 | 94.41 | +14.1% | 97.17 | +10.9% |
| Profit before tax | 17.07 | 10.41 | +64.0% | 14.73 | +15.9% |
| Net profit for the period | 12.87 | 7.91 | +62.7% | 11.15 | +15.4% |
| EPS, basic (₹) | 7.78 | 4.78 | +62.8% | 6.74 | +15.4% |
| Net margin (%) | 12.0 | 8.4 | 11.5 |
Standalone
- Filed with BSE
- 25 Jan 2021, 19:05 IST
- Board meeting
- 25 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE